PalmerL, and SmaldoneG: The unfulfilled promise of inhaled therapy in ventilator-associated infections: Where do we go from here?. J Aerosol Med Pulm Drug Deliv. 2022; 35:11–24.
2.
NiedermanMS, AlderJ, BassettiM, BoatengF, CaoB, CorkeryK, DhandR, KayeKS, LawatscheckR, McLerothP, NicolauDP, WangC, WoodGC, WunderinkRG, and ChastreJ: Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): A double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infect Dis. 2020; 20:330–340.
3.
KollefMH, RicardJD, RouxD, FrancoisB, IschakiE, RozgonyiZ, BoulainT, IvanyiZ, JánosG, GarotD, KouraF, ZakynthinosE, DimopoulosG, TorresA, DankerW, and MontgomeryAB: A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of gram-negative ventilator-associated pneumonia: IASIS trial. Chest. 2017; 151:1239–1246.
4.
KadrichuN, and DaniherD: Improvement of an in vitro model to assess delivered dose and particle size for a vibrating mesh nebulizer during mechanical ventilation. J Aerosol Med Pulm Drug Deliv. 2018; 31:94–102.
